EXEL Exelixis Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 12 January 2020 Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

   – Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates – – Presentation and webcast at 2020 J.P.

2. 07 January 2020 Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

   — Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

3. 07 January 2020 Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

   – Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on

4. 19 December 2019 Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

   – New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration

5. 13 December 2019 Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

   Exelixis, Inc. (NASDAQ:EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF

6. 26 November 2019 Exelixis Announces Webcasts of Investor Conference Presentations in December

   – Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis' management team will provide an overview of the company at the following investor conferences

7. 12 November 2019 Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

   – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

8. 12 November 2019 Exelixis' Partner Ipsen Announces Health Canada's Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

   – Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen

9. 07 November 2019 Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

   -- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (NASDAQ:EXEL)

10. 31 October 2019 Invenra Announces Expansion of Collaboration with Exelixis

    Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (NASDAQ:EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies

11. 30 October 2019 Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis,

12. 25 September 2019 Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference,

13. 03 September 2019 Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview